+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06765109

A Phase 3 Trial Comparing Neladalkib NVL-655 and Alectinib for First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer

Led by Nuvalent Inc. · Updated on 2026-09-30

450

Participants Needed

159

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating neladalkib NVL-655 compared to alectinib in patients with treatment-naive, ALK-positive advanced Non-Small Cell Lung Cancer NSCLC. This Phase 3, randomized, controlled, open-label study aims to see if neladalkib can better prolong progression-free survival in this patient population. Patients have confirmed ALK rearrangement and have not received prior systemic anticancer treatment for NSCLC except certain chemotherapy under specific conditions. Participants are randomly assigned in equal numbers to receive either neladalkib at 150mg once daily or alectinib at 600mg twice daily, both given orally. The study treatment continues as per protocol, with approximately 225 patients in each treatment arm. This trial evaluates multiple outcomes including progression-free survival, overall survival, intracranial response rates, and safety measures over a period of up to five years after the first patient is dosed. Throughout the study, participants undergo regular assessments including imaging to measure tumor response and progression, laboratory tests to monitor safety, and patient-reported questionnaires to evaluate quality of life and lung cancer symptoms. Safety and adverse events are closely monitored. The total duration of participation can last up to five years, allowing for long-term observation of treatment effects and outcomes.

CONDITIONS

Brief Title

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Research Team

N

Nuvalent Clinical Trials

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here